Here we evaluate the capacity of patient-derived organoids (PDOs) to predict clinical drug response and functional consequences of tumor heterogeneity. We included 36 whole-genome-characterized PDOs from 23 OC patients with known clinical histories.

To standardize interpretation and enhance scientific communication in the field of cancer precision medicine, we revisit the concept of PDO-based drug sensitivity testing (DST). We present an expert consensus-driven approach for medication selection aimed at predicting patient responses.

Sep 27, 2024 · Patient-derived organoids (PDOs) replicate the structure and function of human tissues to address important questions in cancer research. In this review, Tong and colleagues discuss methodologies of PDO cultures, drug screening, biomarker discovery, and their potential for guiding personalized treatment in clinical practice.

Feb 23, 2018 · Patient-derived organoids (PDOs) have recently emerged as robust preclinical models; however, their potential to predict clinical outcomes in patients has remained unclear. We report on a living biobank of PDOs from metastatic, heavily pretreated colorectal and gastroesophageal cancer patients recruited in phase 1/2 clinical trials.

Sep 30, 2023 · In this review, the limitations of the traditional in vitro and in vivo assays, the use of PDOs, the challenges including some tips and tricks of PDO generation in EOC, and the future perspectives, will be discussed.

Jul 1, 2022 · Patient-derived tumour organoids (PDOs), three-dimensional (3D) self-assembled organotypic structures, have revolutionised our understanding of cancer biology and the applications of personalised therapies.

Nov 12, 2024 · Patient-derived organoids (PDOs) are revolutionizing cancer research, enhancing drug testing and personalized treatment through advanced 3D modeling techniques.

Nov 14, 2024 · ‍ ‍ ‍ ‍ ‍ ‍ ‍ In the dynamic field of cancer research, patient-derived organoids (PDOs) have emerged as a groundbreaking approach, promising to transform our understanding and treatment of this complex disease.

Aug 12, 2021 · Recent advances in organoid technology, particularly patient-derived organoids (PDOs), have become a cornerstone in personalized medicine and cancer drug discovery. The PDOs are generated by culturing primary cancer cells from patients in three-dimensional...

Patient-derived models of cancer (PDMC), such as patient-derived xenografts (PDXs) and patient-derived organoids (PDOs), have been developed aiming to address the limitations of the conventional models. Both PDO and PDX capture the clinical heterogeneity of cancer in terms of stage, molecular features, and genetic background.